Multiple Myeloma Treatment Advances Promote a Future of Individualized Patient Care
Jeffrey V. Matous, MD, highlights takeaways from the phase 3 IKEMA trial and notes the benefits of administering CAR T-cell therapy in earlier lines, as evidenced in primary results from the phase 3 CARTITUDE-4 trial.
United States Henning Schade Jeffreyv Matous Thomasg Martin Dana Farber Cancer Institute Colorado Blood Cancer Institute In Denver
Source: onclive.com